US 12,110,277 B2
Synthesis of nirogacestat
Kristin Patterson, Stamford, CT (US); and Mark Hatcher, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed on Sep. 1, 2022, as Appl. No. 17/929,153.
Claims priority of provisional application 63/239,696, filed on Sep. 1, 2021.
Prior Publication US 2023/0089434 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 233/88 (2006.01); C07C 227/26 (2006.01); C07D 263/44 (2006.01)
CPC C07D 233/88 (2013.01) [C07C 227/26 (2013.01); C07D 263/44 (2013.01)] 13 Claims
 
1. A pharmaceutical composition comprising:
(1) 98.0% to 99.9% of nirogacestat, or a pharmaceutically acceptable salt thereof; and
(2) 0.6% to 0.01% of Compound 2

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein the composition is substantially free of Compound 13

OG Complex Work Unit Chemistry